Results 71 to 80 of about 15,382 (226)

The complement model disease paroxysmal nocturnal hemoglobinuria

European Journal of Immunology
We describe initial, current, and future aspects of complement activation and inhibition in the rare hematological disease paroxysmal nocturnal hemoglobinuria (PNH).
Christoph Q. Schmidt, B. Höchsmann, H. Schrezenmeier   +2 more
semanticscholar   +1 more source

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.

Blood, 2020
Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete suppression of the terminal complement pathway and the high serum concentration ...
A. Röth, J. Nishimura, Z. Nagy, Júlia Gaál-Weisinger, J. Panse, S. Yoon, M. Egyed, S. Ichikawa, Yoshikazu Ito, Jin Seok Kim, H. Ninomiya, H. Schrezenmeier, S. Sica, K. Usuki, F. Sicre de Fontbrune, J. Soret, A. Sostelly, J. Higginson, A. Dieckmann, B. Gentile, J. Anzures‐Cabrera, K. Shinomiya, Gregor Jordan, Marta Biedzka-Sarek, B. Klughammer, A. Jahreis, C. Bucher, R. Peffault de Latour   +27 more
semanticscholar   +1 more source

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco‐Hematology

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Objectives Digital morphology (DM) systems assisted by artificial intelligence are increasingly being introduced into hematology laboratories; however, data on their performance in routine clinical practice for bone marrow aspirates (BMA) remain limited.
Gina Zini, John Marra, Elena Rossi, Silvia Bellesi, Nicoletta Pelliccioni, Giuseppe d'Onofrio, Patrizia Chiusolo   +6 more
wiley   +1 more source

Short-term recurrent coronary artery thrombosis with acute myocardial infarction in a patient with aplastic anemia–paroxysmal nocturnal hemoglobinuria syndrome: a case report

Frontiers in Cardiovascular Medicine
BackgroundAcute myocardial infarction commonly occurs in patients with coronary artery disease, but rarely, it can develop under a hypercoagulable state.
Xue-Guo Fu, Yan-Hua Guo, Shi-Chao Wang, Wen-Quan Zhang   +3 more
doaj   +1 more source

Very severe aplastic anemia in an 80‐year‐old man

Clinical Case Reports, 2021
Although the patient with very severe aplastic anemia might be a fit elderly receiving standard therapy, there are factors which contribute to an adverse outcome such as severity of pancytopenia, absence of minor paroxysmal nocturnal hemoglobinuria clone
Ganesh Kasinathan, Bee Sun Lee, Jameela Sathar   +2 more
doaj   +1 more source

Treatment of paroxysmal nocturnal hemoglobinuria [PDF]

Blood, 1982
Patients with PNH may be treated with a number of known agents. As in all patients with a chronic disease, a regimen tolerable over a long period of time must be selected. Knowledge and anticipation of complications and their proper treatment are essential parts in the treatment.
openaire   +3 more sources

COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria

Blood, 2021
Complement has emerged as a likely driver of the immune response and end-organ damage in COVID-19. In patients with severe disease, deposition of terminal complement and micro-thrombosis have been observed in the lung, skin, kidney, and heart.
G. Gerber, Xuan Yuan, Jia Yu, Benjamin A. Y. Cher, Evan M. Braunstein, S. Chaturvedi, R. Brodsky   +6 more
semanticscholar   +1 more source

Mapping of C5‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition

Immunology, EarlyView.
We identify four distinct C5 inhibitory epitopes, including two novel antibodies that selectively block membrane attack complex (MAC) assembly while preserving C5 cleavage and C5a generation. These findings establish selective MAC inhibition as a new therapeutic strategy for complement‐mediated diseases.
Rebekah Sian Cooke, Kok Yung Lee, Georgina Elizabeth Menzies, Masashi Mizuno, Bryan Paul Morgan, Wioleta Milena Zelek   +5 more
wiley   +1 more source

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Haematologica, 2012
Background Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation.
Jeffrey J. Pu, Rong Hu, Galina L. Mukhina, Hetty E. Carraway, Michael A. McDevitt, Robert A. Brodsky   +5 more
doaj   +1 more source

The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments

Expert Review of Clinical Pharmacology, 2022
Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled activation of the terminal complement pathway, leading to intravascular hemolysis (IVH) and a prothrombotic state. Treatment with terminal complement (C5) inhibitors,
Jong Wook Lee, R. Brodsky, J. Nishimura, A. Kulasekararaj   +3 more
semanticscholar   +1 more source